Portage Biotechの空売り状況は、投資家がPortage Biotechの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Portage Biotech (NASDAQ:PRTG) 株価情報, 空売り情報

Portage Biotech

Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.

Portage Biotech Inc

<p>CVR Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVI#NYSE">CVI</a>) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(0.89) by 34.83 percent. This is a 1550 percent decrease over earnings of $0.04 per share from the same period last year.  The company reported quarterly sales of $1.65 billion which beat the analyst consensus estimate of $1.31 billion by 25.82 percent.  This is a 11.65 percent decrease over sales of $1.86 billion the same period last year.</p>


Earnings

Earnings Beats

News

CVR Energy Q1 Adj. EPS $(0.58) Beats $(0.89) Estimate, Sales $1.65B Beat $1.31B Estimate

Biotech

General

NGNE

Neurogene To Give Oral Presentation On Monitoring And Treatment To Reverse Rare Complication of High-Dose Gene Therapy At the ASGCT Annual Meeting

Earnings Misses

Waste Management Q1 Adj. EPS $1.67 Beats $1.62 Estimate, Sales $6.02B Miss $6.12B Estimate

<p>Brown &amp; Brown (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRO#NYSE">BRO</a>) reported quarterly earnings of $1.29 per share which missed the analyst consensus estimate of $1.30 by 0.77 percent. This is a 13.16 percent increase over earnings of $1.14 per share from the same period last year.  The company reported quarterly sales of $1.40 billion which met the analyst consensus estimate.  This is a 11.61 percent increase over sales of $1.26 billion the same period last year.</p>


Brown & Brown Q1 Adj. EPS $1.29 Misses $1.30 Estimate, Sales $1.40B Inline

<p>Scotiabank  analyst Kevin Krishnaratne   downgrades Lightspeed Commerce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LSPD#NYSE">LSPD</a>) from Sector Outperform to Sector Perform and lowers the price target from $17 to $11.</p>


Downgrades

Price Target

Analyst Ratings

LSPD

Scotiabank Downgrades Lightspeed Commerce to Sector Perform, Lowers Price Target to $11

<h3>Gainers</h3>
<ul>
<li><strong>Leggett &amp; Platt</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEG#NYSE">LEG</a>) shares moved upwards by 17.6% to $8.55 during Monday's after-market session. The market value of their outstanding shares is at $1.1 billion. The company's, Q1 earnings came out today. </li>
<li><strong>Beyond</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYON#NYSE">BYON</a>) shares moved upwards by 16.02% to $4.85. The market value of their outstanding shares is at $257.7 million. As per the news, the Q1 earnings report came out today. </li>
<li><strong>SunCar Tech Gr</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDA#NASDAQ">SDA</a>) shares moved upwards by 15.38% to $3.0. The company's market cap stands at $325.8 million. As per the news, the FY earnings report came out today. </li>
<li><strong>Yoshiharu Global</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YOSH#NASDAQ">YOSH</a>) stock rose 7.6% to $13.01. The company's market cap stands at $22.4 million. </li>
<li><strong>Gogoro</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GGR#NASDAQ">GGR</a>) stock rose 4.99% to $0.27. The market value of their outstanding shares is at $79.3 million. </li>
<li><strong>Wah Fu Education Gr</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WAFU#NASDAQ">WAFU</a>) stock increased by 4.9% to $1.5. The company's market cap stands at $6.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>WW International</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WW#NASDAQ">WW</a>) stock declined by 12.9% to $0.36 during Monday's after-market session. The company's market cap stands at $28.9 million. </li>
<li><strong>Wag Group</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) shares fell 10.32% to $0.15. The market value of their outstanding shares is at $7.4 million. </li>
<li><strong>Aureus Greenway Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGH#NASDAQ">AGH</a>) stock declined by 6.31% to $0.57. The market value of their outstanding shares is at $7.9 million. </li>
<li><strong>Hall Of Fame Resort</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOFV#NASDAQ">HOFV</a>) stock fell 5.39% to $0.68. The market value of their outstanding shares is at $4.4 million. </li>
<li><strong>Damon</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMN#NASDAQ">DMN</a>) shares declined by 5.27% to $0.0. The market value of their outstanding shares is at $2.8 million. </li>
<li><strong>Grove Collaborative Hldgs</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GROV#NYSE">GROV</a>) stock fell 5.23% to $1.05. The company's market cap stands at $42.2 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Movers

BYON

GROV

HOFV

Market Index Target Term Securities Linked To The Dow Jones Industrial Average

WAFU

YOSH

12 Consumer Discretionary Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li><strong>Tevogen Bio Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) stock moved upwards by 40.8% to $1.32 during Monday's after-market session. The market value of their outstanding shares is at $231.0 million. </li>
<li><strong>CytomX Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) stock increased by 8.77% to $0.77. The market value of their outstanding shares is at $61.6 million. </li>
<li><strong>Autonomix Medical</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) stock rose 8.29% to $2.48. The market value of their outstanding shares is at $6.1 million. </li>
<li><strong>Onconetix</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) stock rose 7.9% to $0.09. The company's market cap stands at $1.3 million. </li>
<li><strong>Cyclacel Pharmaceuticals</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares moved upwards by 6.55% to $0.3. The market value of their outstanding shares is at $4.2 million. </li>
<li><strong>Genfit</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNFT#NASDAQ">GNFT</a>) stock increased by 6.16% to $3.79. The market value of their outstanding shares is at $188.9 million. The company's, FY earnings came out 2 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Anavex Life Sciences</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) shares declined by 12.6% to $8.37 during Monday's after-market session. The company's market cap stands at $712.2 million. </li>
<li><strong>Y-mAbs Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) shares decreased by 10.38% to $3.8. The market value of their outstanding shares is at $170.1 million. </li>
<li><strong>Forian</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORA#NASDAQ">FORA</a>) shares fell 8.97% to $1.93. The market value of their outstanding shares is at $60.2 million. </li>
<li><strong>Relmada Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLMD#NASDAQ">RLMD</a>) shares decreased by 8.53% to $0.33. The company's market cap stands at $10.7 million. </li>
<li><strong>DBV Technologies</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) shares fell 7.31% to $8.5. The market value of their outstanding shares is at $232.3 million. </li>
<li><strong>Lipella Pharmaceuticals</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIPO#NASDAQ">LIPO</a>) stock declined by 6.95% to $2.41. The company's market cap stands at $6.1 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


AMIX

AVXL

CTMX

CYCC

DBVT

FORA

GNFT

LIPO

ONCO

RLMD

TVGN

YMAB

12 Health Care Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li><strong>ATIF Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBAI#NASDAQ">ZBAI</a>) shares increased by 10.0% to $1.1 during Monday's after-market session. The market value of their outstanding shares is at $19.0 million. </li>
<li><strong>Royalty Management Hldgs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMCO#NASDAQ">RMCO</a>) stock increased by 7.7% to $1.26. The company's market cap stands at $18.8 million. </li>
<li><strong>Odyssey Marine Explr</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMEX#NASDAQ">OMEX</a>) shares moved upwards by 7.16% to $1.42. The company's market cap stands at $41.3 million. </li>
<li><strong>Stardust Power</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDST#NASDAQ">SDST</a>) shares increased by 4.92% to $0.52. The company's market cap stands at $27.4 million. </li>
<li><strong>Icon Energy</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICON#NASDAQ">ICON</a>) shares moved upwards by 4.87% to $2.15. The market value of their outstanding shares is at $4.6 million. As per the news, the FY earnings report came out 3 days ago. </li>
<li><strong>BioNexus Gene Lab</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGLC#NASDAQ">BGLC</a>) shares moved upwards by 4.79% to $2.84. The market value of their outstanding shares is at $5.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>WF Holding</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WFF#NASDAQ">WFF</a>) shares decreased by 7.9% to $3.52 during Monday's after-market session. The company's market cap stands at $87.8 million. </li>
<li><strong>Zeo Energy</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZEO#NASDAQ">ZEO</a>) stock declined by 7.37% to $1.51. The market value of their outstanding shares is at $21.1 million. </li>
<li><strong>OceanPal</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OP#NASDAQ">OP</a>) shares decreased by 5.84% to $0.71. The company's market cap stands at $5.3 million. </li>
<li><strong>Azul</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZUL#NYSE">AZUL</a>) stock declined by 5.68% to $0.83. The market value of their outstanding shares is at $255.7 million. </li>
<li><strong>VCI Global</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCIG#NASDAQ">VCIG</a>) stock fell 4.98% to $4.5. The market value of their outstanding shares is at $12.6 million. </li>
<li><strong>Kforce</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KFRC#NYSE">KFRC</a>) stock fell 4.85% to $40.69. The company's market cap stands at $777.6 million. As per the news, the Q1 earnings report came out today.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


AZUL

BGLC

ICON

KFRC

OMEX

RMCO

SDST

VCIG

ZBAI

12 Industrials Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li><strong>Sagtec Global</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGT#NASDAQ">SAGT</a>) shares moved upwards by 7.3% to $4.12 during Monday's after-market session. The company's market cap stands at $51.7 million. </li>
<li><strong>Sigmatron Intl</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMA#NASDAQ">SGMA</a>) shares rose 5.88% to $1.26. The market value of their outstanding shares is at $7.7 million. </li>
<li><strong>Cyngn</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) stock increased by 5.13% to $4.71. The market value of their outstanding shares is at $8.2 million. </li>
<li><strong>Mobix Labs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOBX#NASDAQ">MOBX</a>) shares increased by 4.99% to $0.76. The market value of their outstanding shares is at $31.0 million. </li>
<li><strong>Taoping</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TAOP#NASDAQ">TAOP</a>) shares rose 4.95% to $0.24. The market value of their outstanding shares is at $3.1 million. </li>
<li><strong>Veritone</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERI#NASDAQ">VERI</a>) stock increased by 4.83% to $2.17. The market value of their outstanding shares is at $97.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>UTime</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTO#NASDAQ">WTO</a>) stock decreased by 12.7% to $1.9 during Monday's after-market session. The market value of their outstanding shares is at $49.0 million. </li>
<li><strong>Sanmina</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANM#NASDAQ">SANM</a>) shares decreased by 8.34% to $74.0. The company's market cap stands at $3.9 billion. As per the press release, Q2 earnings came out today. </li>
<li><strong>Intrusion</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTZ#NASDAQ">INTZ</a>) stock declined by 6.62% to $1.27. The market value of their outstanding shares is at $25.2 million. </li>
<li><strong>Ultra Clean Hldgs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCTT#NASDAQ">UCTT</a>) stock fell 6.06% to $20.95. The market value of their outstanding shares is at $945.5 million. The company's, Q1 earnings came out today. </li>
<li><strong>Mawson Infra Gr</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIGI#NASDAQ">MIGI</a>) shares decreased by 5.43% to $0.68. The company's market cap stands at $12.7 million. </li>
<li><strong>908 Devices</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASS#NASDAQ">MASS</a>) stock declined by 4.97% to $5.07. The company's market cap stands at $179.1 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


INTZ

MASS

MAWSON INFRSTRUCTURE GRP by Mawson Infrastructure Group Inc.

MIGI

MOBX

SAGT

SANM

SGMA

TAOP

UCTT

VERI

12 Information Technology Stocks Moving In Monday's After-Market Session

<p><strong>Nucor Corp</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) reported first-quarter financial results after the market close on Monday. Here&#8217;s what you need to know <a href="https://www.benzinga.com/pressreleases/25/04/n45053335/nucor-reports-results-for-the-first-quarter-of-2025">from the report</a>.</p>
<ul>
<li><strong>Q1 Revenue: </strong>$7.83 billion, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $7.23 billion</li>
</ul>
<ul>
<li><strong>Q1 Adjusted EPS:</strong> 77 cents, versus estimates of 64 cents</li>
</ul>
<p>Total revenue was down 4% on a year-over-year basis. The steel manufacturer said it shipped approximately 6.83 million tons to outside customers during the quarter. Average sales price per ton decreased&nbsp;12%&nbsp;year-over-year, while total steel mill shipments increased 10% year-over-year.</p>
<p>Nucor repurchased approximately 2.3 million shares at an average price of $133.17 per share in the quarter. The steel company had $806 million remaining on its buyback as of April 5. Nucor ended the quarter with $4.06 billion in cash, cash equivalents and short-term investments on hand.&nbsp;</p>
<p>&#8220;Despite recent financial market volatility, Nucor is seeing solid demand for the steel and steel products we manufacture. Our healthy balance sheet and diverse product portfolio position us well, even in uncertain times,&#8221; said&nbsp;<strong>Leon Topalian</strong>, chair, president and CEO of Nucor.</p>
<p><strong>See Also: <a href="https://www.benzinga.com/news/management/25/04/45053723/nxp-semiconductors-reports-q1-earnings-very-uncertain-operating-environment-tied-to-tariffs-ceo-transition-shares-fall">NXP Semiconductors Reports Q1 Earnings: &#8216;Very Uncertain&#8217; Operating Environment Tied To Tariffs, CEO Transition, Shares Fall</a></strong></p>
<p><strong>Outlook:</strong> Nucor expects second-quarter earnings to increase across all three operating segments (steel mills, steel products and raw materials) compared to the first quarter. </p>
<p>The stock reaction is somewhat muted, likely due to the company already reporting preliminary results for the quarter in March. Executives will further discuss the quarter on a call with investors and analysts Tuesday morning at 10 a.m. ET.</p>
<p><strong>NUE Price Action:</strong> <a href="http://benzinga.com/quote/nue" target="_blank" rel="noreferrer noopener">Nucor shares</a> were up 1.02% after-hours, trading at $117.76 at the time of publication Monday, per <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.</p>
<p><em>Photo: saweang.w/Shutterstock.</em></p>


Guidance

Commodities

After-Hours Center

Nucor Q1 Earnings: Revenue Beat, EPS Beat, 'Solid' Steel Demand And More

<p>Travelzoo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TZOO#NASDAQ">TZOO</a>) is preparing to release its quarterly earnings on Tuesday, 2025-04-29. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Travelzoo to report an <strong>earnings per share</strong> (EPS) of $0.25.</p>
<p>Investors in Travelzoo are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Overview of Past Earnings</h3>
<p>In the previous earnings release, the company missed EPS by $0.04, leading to a 10.38% increase in the share price the following trading session.</p>
<p>Here's a look at Travelzoo's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.30</td>
<td>0.20</td>
<td>0.22</td>
<td>0.30</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.26</td>
<td>0.26</td>
<td>0.23</td>
<td>0.31</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>10.0%</td>
<td>3.0%</td>
<td>7.000000000000001%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745874187_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Travelzoo were trading at $13.32 as of April 25. Over the last 52-week period, shares are up 40.52%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/TZOO/earnings"><strong>To track all earnings releases for Travelzoo visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


TZOO

A Peek at Travelzoo's Future Earnings

<p><strong>Intrusion</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTZ#NASDAQ">INTZ</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-04-29. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Intrusion will report an <strong>earnings per share</strong> (EPS) of $-0.11. </p>
<p>Anticipation surrounds Intrusion's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Historical Earnings Performance</h3>
<p>The company's EPS missed by $0.15 in the last quarter, leading to a 21.3% drop in the share price on the following day.</p>
<p>Here's a look at Intrusion's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.21</td>
<td>-0.42</td>
<td>-0.55</td>
<td>-1.20</td>
<td>-2.2</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.36</td>
<td>-0.35</td>
<td>-0.53</td>
<td>-0.94</td>
<td>-1.8</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-21.0%</td>
<td>-15.0%</td>
<td>19.0%</td>
<td>-26.0%</td>
<td>-9.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745874178_0.png" alt="eps graph" /></p>
<h3>Performance of Intrusion Shares</h3>
<p>Shares of Intrusion were trading at $1.26 as of April 25. Over the last 52-week period, shares are down 21.84%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/INTZ/earnings"><strong>To track all earnings releases for Intrusion visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Peek at Intrusion's Future Earnings

<p><strong>Rocky Brands</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKY#NASDAQ">RCKY</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-04-29. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Rocky Brands will report an <strong>earnings per share</strong> (EPS) of $0.52. </p>
<p>Investors in Rocky Brands are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Performance in Previous Earnings</h3>
<p>The company's EPS missed by $0.03 in the last quarter, leading to a 10.9% drop in the share price on the following day.</p>
<p>Here's a look at Rocky Brands's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.22</td>
<td>0.98</td>
<td>0.09</td>
<td>0.02</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.19</td>
<td>0.77</td>
<td>0.17</td>
<td>0.41</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-11.0%</td>
<td>-27.0%</td>
<td>-2.0%</td>
<td>28.000000000000004%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745874157_0.png" alt="eps graph" /></p>
<h3>Tracking Rocky Brands's Stock Performance</h3>
<p>Shares of Rocky Brands were trading at $13.7 as of April 25. Over the last 52-week period, shares are down 47.77%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/RCKY/earnings"><strong>To track all earnings releases for Rocky Brands visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


RCKY

Rocky Brands Earnings Preview

<p>Zynex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) will release its quarterly earnings report on Tuesday, 2025-04-29. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Zynex to report an <strong>earnings per share</strong> (EPS) of $-0.24.</p>
<p>The announcement from Zynex is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Past Earnings Performance</h3>
<p>The company's EPS missed by $0.11 in the last quarter, leading to a 51.29% drop in the share price on the following day.</p>
<p>Here's a look at Zynex's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.09</td>
<td>0.06</td>
<td>0.08</td>
<td>0.03</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.02</td>
<td>0.07</td>
<td>0.04</td>
<td>0</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-51.0%</td>
<td>6.0%</td>
<td>-12.0%</td>
<td>7.000000000000001%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745874149_0.png" alt="eps graph" /></p>
<h3>Zynex Share Price Analysis</h3>
<p>Shares of Zynex were trading at $2.41 as of April 25. Over the last 52-week period, shares are down 79.54%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. </p>
<h3>Analyst Opinions on Zynex</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Zynex.</p>
<p>Zynex has received a total of 2 ratings from analysts, with the consensus rating as Buy. With an average one-year price target of $10.25, the consensus suggests a potential 325.31% upside.</p>
<h3>Comparing Ratings Among Industry Peers</h3>
<p>The below comparison of the analyst ratings and average 1-year price targets of Fractyl Health, Hyperfine and CytoSorbents, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Fractyl Health, with an average 1-year price target of $11.0, suggesting a potential 356.43% upside.</li>
<li>Analysts currently favor an Buy trajectory for Hyperfine, with an average 1-year price target of $1.33, suggesting a potential 44.81% downside.</li>
<li>Analysts currently favor an Buy trajectory for CytoSorbents, with an average 1-year price target of $7.0, suggesting a potential 190.46% upside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
<p>The peer analysis summary outlines pivotal metrics for Fractyl Health, Hyperfine and CytoSorbents, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zynex</td>
<td>Buy</td>
<td>-2.77%</td>
<td>$35.99M</td>
<td>-1.72%</td>
</tr>
<tr>
<td>Fractyl Health</td>
<td>Buy</td>
<td>-57.14%</td>
<td>$3K</td>
<td>-63.42%</td>
</tr>
<tr>
<td>Hyperfine</td>
<td>Buy</td>
<td>-13.59%</td>
<td>$826K</td>
<td>-19.36%</td>
</tr>
<tr>
<td>CytoSorbents</td>
<td>Buy</td>
<td>24.52%</td>
<td>$9.40M</td>
<td>-65.41%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Zynex ranks at the top for Revenue Growth and Gross Profit among its peers. However, it ranks at the bottom for Return on Equity. Overall, Zynex is performing well in terms of revenue and profit compared to its peers, but its return on equity is lower in comparison.</p>
<h3>About Zynex</h3>
<p>Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company operates business as one operating segment which includes two revenue types: Devices and Supplies. Its markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others.</p>
<h3>Financial Milestones: Zynex's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Zynex's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately <strong>-2.77%</strong>. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Zynex's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-1.34%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Zynex's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-1.72%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Zynex's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-0.5%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>2.07</strong>, caution is advised due to increased financial risk.</p>
<p><a href="https://www.benzinga.com/quote/ZYXI/earnings"><strong>To track all earnings releases for Zynex visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


ZYXI

Earnings Outlook For Zynex

<p><strong>Stem</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-04-29. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Stem will report an <strong>earnings per share</strong> (EPS) of $-0.14. </p>
<p>The announcement from Stem is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Earnings History Snapshot</h3>
<p>In the previous earnings release, the company missed EPS by $0.13, leading to a 13.07% increase in the share price the following trading session.</p>
<p>Here's a look at Stem's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.18</td>
<td>-0.21</td>
<td>-0.22</td>
<td>-0.21</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.31</td>
<td>-0.27</td>
<td>-0.22</td>
<td>-0.46</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>13.0%</td>
<td>-22.0%</td>
<td>-41.0%</td>
<td>-28.999999999999996%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745874127_0.png" alt="eps graph" /></p>
<h3>Tracking Stem's Stock Performance</h3>
<p>Shares of Stem were trading at $0.4154 as of April 25. Over the last 52-week period, shares are down 77.23%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/STEM/earnings"><strong>To track all earnings releases for Stem visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


STEM

A Preview Of Stem's Earnings

<p>Northeast Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBN#NASDAQ">NBN</a>) will release its quarterly earnings report on Tuesday, 2025-04-29. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Northeast Bank to report an <strong>earnings per share</strong> (EPS) of $2.78.</p>
<p>The market awaits Northeast Bank's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Historical Earnings Performance</h3>
<p>In the previous earnings release, the company beat EPS by $0.17, leading to a 3.03% increase in the share price the following trading session.</p>
<p>Here's a look at Northeast Bank's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2025</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.57</td>
<td>1.77</td>
<td>1.79</td>
<td>1.72</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.74</td>
<td>2.11</td>
<td>1.91</td>
<td>1.83</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>3.0%</td>
<td>3.0%</td>
<td>1.0%</td>
<td>3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745874116_0.png" alt="eps graph" /></p>
<h3>Market Performance of Northeast Bank's Stock</h3>
<p>Shares of Northeast Bank were trading at $91.1 as of April 25. Over the last 52-week period, shares are up 78.67%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/NBN/earnings"><strong>To track all earnings releases for Northeast Bank visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Uncovering Potential: Northeast Bank's Earnings Preview

<p><strong>Global Industrial</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIC#NYSE">GIC</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-04-29. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Global Industrial will report an <strong>earnings per share</strong> (EPS) of $0.20. </p>
<p>Investors in Global Industrial are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Performance in Previous Earnings</h3>
<p>During the last quarter, the company reported an EPS missed by $0.01, leading to a 0.41% drop in the share price on the subsequent day.</p>
<p>Here's a look at Global Industrial's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.28</td>
<td>0.58</td>
<td>0.51</td>
<td>0.38</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.27</td>
<td>0.44</td>
<td>0.52</td>
<td>0.34</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-0.0%</td>
<td>-21.0%</td>
<td>-3.0%</td>
<td>-10.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745874106_0.png" alt="eps graph" /></p>
<h3>Global Industrial Share Price Analysis</h3>
<p>Shares of Global Industrial were trading at $22.12 as of April 25. Over the last 52-week period, shares are down 42.77%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/GIC/earnings"><strong>To track all earnings releases for Global Industrial visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Examining the Future: Global Industrial's Earnings Outlook

<p>LSB Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LXU#NYSE">LXU</a>) will release its quarterly earnings report on Tuesday, 2025-04-29. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate LSB Industries to report an <strong>earnings per share</strong> (EPS) of $0.04.</p>
<p>Investors in LSB Industries are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Historical Earnings Performance</h3>
<p>The company's EPS missed by $0.04 in the last quarter, leading to a 4.03% drop in the share price on the following day.</p>
<p>Here's a look at LSB Industries's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.11</td>
<td>-0.07</td>
<td>0.11</td>
<td>0.05</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.07</td>
<td>-0.11</td>
<td>0.13</td>
<td>0.08</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-4.0%</td>
<td>-3.0%</td>
<td>3.0%</td>
<td>13.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745874097_0.png" alt="eps graph" /></p>
<h3>Tracking LSB Industries's Stock Performance</h3>
<p>Shares of LSB Industries were trading at $5.65 as of April 25. Over the last 52-week period, shares are down 36.67%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Analyst Insights on LSB Industries</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on LSB Industries.</p>
<p>A total of 1 analyst ratings have been received for LSB Industries, with the consensus rating being Buy. The average one-year price target stands at $8.0, suggesting a potential 41.59% upside.</p>
<h3>Understanding Analyst Ratings Among Peers</h3>
<p>The below comparison of the analyst ratings and average 1-year price targets of Intrepid Potash, Aspen Aerogels and Koppers Hldgs, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Sell trajectory for Intrepid Potash, with an average 1-year price target of $20.0, suggesting a potential 253.98% upside.</li>
<li>Analysts currently favor an Buy trajectory for Aspen Aerogels, with an average 1-year price target of $16.8, suggesting a potential 197.35% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Koppers Hldgs, with an average 1-year price target of $64.0, suggesting a potential 1032.74% upside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
<p>The peer analysis summary offers a detailed examination of key metrics for Intrepid Potash, Aspen Aerogels and Koppers Hldgs, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>LSB Industries</td>
<td>Buy</td>
<td>1.73%</td>
<td>$6.05M</td>
<td>-1.85%</td>
</tr>
<tr>
<td>Intrepid Potash</td>
<td>Sell</td>
<td>-1.52%</td>
<td>$7.29M</td>
<td>-35.85%</td>
</tr>
<tr>
<td>Aspen Aerogels</td>
<td>Buy</td>
<td>46.15%</td>
<td>$47.13M</td>
<td>2.02%</td>
</tr>
<tr>
<td>Koppers Hldgs</td>
<td>Outperform</td>
<td>-7.05%</td>
<td>$83.60M</td>
<td>-2.00%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>LSB Industries ranks at the bottom for Revenue Growth and Gross Profit among its peers. It is at the top for Consensus rating and Return on Equity.</p>
<h3>Unveiling the Story Behind LSB Industries</h3>
<p>LSB Industries Inc is engaged in the manufacturing and sale of chemical products in the United States. The company manufactures and sells chemical products for the agricultural and industrial sectors. Its products include ammonia, fertilizer grade ammonium nitrate (AN and HDAN), and urea ammonia nitrate (UAN) for agricultural applications; high purity and commercial grade ammonia, sulfuric acids, concentrated, blended, and regular nitric acid, mixed nitrating acids, carbon dioxide, and diesel exhaust fluid for industrial applications; and industrial grade AN (LDAN) and AN solutions for mining applications. Its products are sold through distributors and directly to end customers throughout the United States and other parts of North America.</p>
<h3>Unraveling the Financial Story of LSB Industries</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Positive Revenue Trend:</strong> Examining LSB Industries's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>1.73%</strong> as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Materials sector.</p>
<p><strong>Net Margin:</strong> LSB Industries's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-6.78%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> LSB Industries's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-1.85%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> LSB Industries's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>-0.77%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>1.06</strong>, LSB Industries faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<p><a href="https://www.benzinga.com/quote/LXU/earnings"><strong>To track all earnings releases for LSB Industries visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Preview Of LSB Industries's Earnings

<p>CECO Environmental (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CECO#NASDAQ">CECO</a>) will release its quarterly earnings report on Tuesday, 2025-04-29. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate CECO Environmental to report an <strong>earnings per share</strong> (EPS) of $0.09.</p>
<p>Anticipation surrounds CECO Environmental's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Earnings Track Record</h3>
<p>During the last quarter, the company reported an EPS beat by $0.04, leading to a 0.04% increase in the share price on the subsequent day.</p>
<p>Here's a look at CECO Environmental's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.23</td>
<td>0.19</td>
<td>0.16</td>
<td>0.11</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.27</td>
<td>0.14</td>
<td>0.20</td>
<td>0.11</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>0.0%</td>
<td>9.0%</td>
<td>4.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745874088_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of CECO Environmental were trading at $19.93 as of April 25. Over the last 52-week period, shares are down 11.19%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/CECO/earnings"><strong>To track all earnings releases for CECO Environmental visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


CECO

CECO Environmental's Earnings Outlook

<p>Stepan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCL#NYSE">SCL</a>) is preparing to release its quarterly earnings on Tuesday, 2025-04-29. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Stepan to report an <strong>earnings per share</strong> (EPS) of $0.60.</p>
<p>Anticipation surrounds Stepan's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Historical Earnings Performance</h3>
<p>The company's EPS missed by $0.21 in the last quarter, leading to a 2.21% increase in the share price on the following day.</p>
<p>Here's a look at Stepan's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.33</td>
<td>0.65</td>
<td>0.67</td>
<td>0.35</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.12</td>
<td>1.03</td>
<td>0.41</td>
<td>0.64</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>2.0%</td>
<td>-3.0%</td>
<td>-5.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745874081_0.png" alt="eps graph" /></p>
<h3>Tracking Stepan's Stock Performance</h3>
<p>Shares of Stepan were trading at $48.24 as of April 25. Over the last 52-week period, shares are down 41.93%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/SCL/earnings"><strong>To track all earnings releases for Stepan visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Insights Ahead: Stepan's Quarterly Earnings

Press Releases

Portage Biotech Reports Results for Fiscal Quarter Ended September 30, 2024

Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter

Portage Biotech Announces Letter of Intent with Immunova for an Option to Acquire iOx Therapeutics, Ltd

Management

Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company

Financing

Portage Biotech Announces Completion of $2.15 Million Private Financing

Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements

Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial

Health Care

Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7

Emerging Tech Quartet – PRSO, LXRX, PRTG, RNAZ – Drive Breakthroughs Across Defense, Obesity, Oncology, and RNA Therapeutics

Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7

LXRX

PRSO

PRTG

RNAZ

ABVC BioPharma

BioVie

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

Equillium

Ernexa Therapeutics

Evaxion Biotech A/S - American Depositary Share

Evaxion Biotech

Geovax Labs

Imunon

IN8bio

Kairos Pharma

Moleculin Biotech

MEI Pharma

Marker Therapeutics

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

NextCure

BiomX

Polyrizon

Rallybio

Synlogic

Cantor Fitzgerald

Oppenheimer

WIIM

Portage Biotech shares are trading higher after the company reported confirmatory preclinical efficacy data for PORT-7.

Comments

Portage Biotech

空売り

Portage Biotech (NASDAQ:PRTG) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル